Cardurion Pharmaceuticals is a biotechnology company that specializes in the discovery and development of therapies intended for cardiovascular disease. Cardurion Pharmaceuticals was founded in 2017 and is headquartered in Burlington, MA. Striving to address the unique needs of patients suffering from heart disease through novel approaches, the team manages the development and clinical trial stages for patients suffering from chronic heart failure along with related therapies that have broad potential for cardiovascular disease treatment.
Cardurion Pharmaceuticals is a biotechnology company that specializes in the discovery and development of therapies intended for cardiovascular disease. Cardurion Pharmaceuticals was founded in 2017 and is headquartered in Burlington, MA. Striving to address the unique needs of patients suffering from heart disease through novel approaches, the team manages the development and clinical trial stages for patients suffering from chronic heart failure along with related therapies that have broad potential for cardiovascular disease treatment.
Cardurion Pharma is a privately held company and is not publicly traded, therefore investing in Cardurion Pharma pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can learn more about Forge’s Secondary Marketplace and how to invest in private companies before their potential IPO. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
Can you sell shares of Cardurion Pharma before it goes public?
You can seek to sell your shares in Cardurion Pharma while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.
What is the pre-IPO value of my Cardurion Pharma shares?
To determine the value of your Cardurion Pharma shares, create a free account to gain access to Forge’s platform. In addition to the Forge Price, Forge Markets contains pricing information for hundreds of pre-IPO companies such as Last Closed Trade Price. A Private Market Specialist will also be available to assist you with any inquiries related to your Cardurion Pharma shares. You can also learn more about how to sell your private shares before getting started.
Is Cardurion Pharma a publicly traded company?
If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.
To learn more about Cardurion Pharma potential IPO
Will Cardurion Pharma go IPO?
Cardurion Pharma has not yet filed for an IPO. However, it’s important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2024.
What is Cardurion Pharma’s IPO price?
The Cardurion Pharma IPO price does not exist at this time, as Cardurion Pharma is still a private company and has not yet conducted an IPO. To explore secondary market data and access private market pricing details and data that may be related to Cardurion Pharma register for Forge Markets, today.
When was Cardurion Pharma founded?
Cardurion Pharma was founded in 2017.
What is Cardurion Pharma funding to date?
Cardurion Pharma has raised $866.77MM to date.
Who are Cardurion Pharma’s major investors?
Bain Capital Private Equity
The Invus Group
Fidelity Management & Research Company
Nea
Millennium Management
Digitalis Ventures
Undisclosed Investors
Blue Owl Healthcare Opportunities
Fidelity Management & Research
Ascenta Capital
Gv
Takeda Pharmeceuticals
Takeda Pharmaceutical
Bain Capital Life Sciences
Polaris Partners
Blue Owl Capital
Deepwork Capital
Farallon Capital Management
Delos Capital
Invus
New Enterprise Associates
Cardurion Pharma Major Investors
Bain Capital Private Equity
The Invus Group
Fidelity Management & Research Company
Nea
Millennium Management
Digitalis Ventures
Undisclosed Investors
Blue Owl Healthcare Opportunities
Fidelity Management & Research
Ascenta Capital
Gv
Takeda Pharmeceuticals
Takeda Pharmaceutical
Bain Capital Life Sciences
Polaris Partners
Blue Owl Capital
Deepwork Capital
Farallon Capital Management
Delos Capital
Invus
New Enterprise Associates
Show All InvestorsShow Fewer Investors
Cardurion Pharma Funding Rounds and Valuation
Funding History Chart
Funding Round Details
Funding Date
Share Class
Amount Raised
Price per Share
Post-Money Valuation
Key Investors
07/16/2024
Series B
$260.41MM
$xx.xx
$754.94MM
Ascenta Capital, Bain Capital Life Sciences, Bain Capital Private Equity, Blue Owl Healthcare Opportunities, Delos Capital, Digitalis Ventures, Farallon Capital Management, Fidelity Management & Research Company, Gv, Invus, Millennium Management, Nea
Price per Share
$xx.xx
Shares Outstanding
53,171,088
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.3x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ascenta Capital, Bain Capital Life Sciences, Bain Capital Private Equity, Blue Owl Healthcare Opportunities, Delos Capital, Digitalis Ventures, Farallon Capital Management, Fidelity Management & Research Company, Gv, Invus, Millennium Management, Nea
07/14/2023
Series A-5
$47.5MM
$xx.xx
$508.61MM
Bain Capital Life Sciences, Bain Capital Private Equity, Polaris Partners, Takeda Pharmeceuticals
Price per Share
$xx.xx
Shares Outstanding
12,101,294
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.3x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Bain Capital Life Sciences, Bain Capital Private Equity, Polaris Partners, Takeda Pharmeceuticals
10/27/2021
Series A-4
$31.38MM
$xx.xx
$425.28MM
Bain Capital Life Sciences, Bain Capital Private Equity, Polaris Partners, Takeda Pharmeceuticals
Price per Share
$xx.xx
Shares Outstanding
9,404,601
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.3x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Bain Capital Life Sciences, Bain Capital Private Equity, Polaris Partners, Takeda Pharmeceuticals
10/27/2021
Series A-3
$99.97MM
$xx.xx
$425.28MM
Bain Capital Life Sciences, Bain Capital Private Equity, Polaris Partners, Takeda Pharmeceuticals
Price per Share
$xx.xx
Shares Outstanding
25,468,730
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.3x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Bain Capital Life Sciences, Bain Capital Private Equity, Polaris Partners, Takeda Pharmeceuticals
PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES
‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.
Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.
Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.
Updated on: Dec 26, 2024
PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES
Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.
The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.
Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.
Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.
Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.
December Private Market Update
